ARCHIVÉ - Supplément


Recommandations canadiennes pour la prévention et le traitement du Paludisme (Malaria) chez les voyageurs internationaux - 2009


1 Singh B, Kim Sung L, Matusop A. Radhakrishnan A, Shamsul SS, Cox-Singh J, Thomas A, Conway DJ. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004;363(9414):1017-24.

2 Jongwutiwes S, Putaporntip C, Iwasaki T, Sata T, Kanbara H. Naturally acquired Plasmodium knowlesi malaria in humans, Thailand. Emerg Infect Dis 2004;10(12):2211-3.

3 Slinger R, Giulivi A, Bodie-Collins M, Hindieh F, John RS, Sher G, Goldman M, Ricketts M, Kain KC. Transfusion-transmitted malaria in Canada. CMAJ 2001;164(3):377-9.

4 Davies HD, Keystone J, Lester ML, Gold R. Congenital malaria in infants of asymptomatic women. CMAJ 1992;146(10):1755-6.

5 World Health Organization. World Malaria Report 2005. Geneva: WHO and UNICEF, 2005.

6 Humar A, Sharma S, Zoutman D, Kain KC. Fatal Falciparum malaria in Canadian travellers. CMAJ 1997; 156(8):1165-7.

7 Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium Falciparum malaria. Nature 2005;434(7030):214-7.

8 Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001;164(5):654-9.

9 Quach C, Kain K, MacPherson D, Mendelson J, MacLean J. Malaria deaths in Canadian travellers. CCDR 1999;25(6):50-3.

10 Watkins K, McCarthy AE, Molnar-Szakacs H, Kwak EJ, Bodie-Collins M. A survey of the accuracy of malaria reporting by the laboratories in Ontario and British Columbia. CCDR 2003;29(14):121-5.

11 MacLean JD, Demers AM, Ndao M, Kokoskin E, Ward BJ, Gyorkos TW. Malaria epidemics and surveillance systems in Canada. Emerg Infect Dis 2007;10(7):1195-201.

12 McCarthy AE, Plourde P, Kuhn S, Bodie M. Parenteral quinine for severe malaria: five year surveillance data from the Canadian Malaria Network. 10th Conference of the International Society of Travel Medicine, May 10-20, 2007. Vancouver, Canada.

13 Murphy GS, Oldfield EC. Falciparum malaria. Infect Dis Clin North Am 1996;10(4):747-75.

14 Loutan L. Malaria: still a threat to travellers. Int J Antimicrob Agents. 2003;21(2):158-63.

15 Steffen R, deBernardis C, Banos A. Travel epidemiology–a global perspective. Int J Antimicrob Agents 2003;21(2):89-95.

16 Leder K, Black J, O'Brien D, Greenwood Z, Kain KC, Schwartz E, Brown G, Torresi J. Malaria in travelers: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2004;39(8):1104-12.

17 Centers for Disease Control and Prevention. Transmission of malaria in resort areas–Dominican Republic, 2004. MMWR Morb Mortal Wkly Rep 2005;53(51-52):1195-8.

18 Centers for Disease Control and Prevention. Malaria– Great Exuma, Bahamas, May-June 2006. MMWR Morb Mortal Wkly Rep 2006;55(37):1013-6.

19 Centers for Disease Control and Prevention. Malaria Surveillance --- United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57(SS05):24-39.

20 Arquin PM, Kozarsky PE, Reed C. CDC Health Information for International Travel 2008. Philadelphia: Elsevier Inc., 2008.

21 Cohen C, Karstaedt A, Frean J, Thomas J, Govender N, Prentice E, Dini L, Galpin J, Crewe-Brown H. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis 2005;41(11):1631-7.

22 Keystone JS. The sound of hoof beats does not always mean that it is a zebra. Clin Infect Dis 2004;39(11):1589-90.

23 Hill DR. Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 2000;7(5):259-66.

24 Gyorkos TW, Svenson JE, MacLean JD, Mohamed N, Remondin MH, Franco ED. Compliance with antimalarial chemoprophylaxis and the subsequent development of malaria: a matched case-control study. Am J Trop Med Hyg 1995;53(5):511-7.

25 Chatterjee S. Compliance of malaria chemoprophylax is among travelers to India. J Travel Med 1999;6(1):7-11.

26 Laver SM, Wetzels J, Behrens RH. Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport. J Travel Med 2001;8(6): 298-303.

27 Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med 2006;13(1):8-14.

28 Banerjee D, Stanley PJ. Malaria chemoprophylaxis in UK general practitioners traveling to South Asia. J Travel Med 2001;8(4):173-5.

29 Molle I, Christensen KL, Hansen PS, Dragsted UB, Aarup M, Buhl MR. Use of medical chemoprophylaxis and antimosquito precautions in Danish malaria patients and their traveling companions. J Travel Med 2000;7(5):253-8.

30 Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, Parise M, Odero M, Waiyaki P. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 2001;8(4):167-72.

31 Leonard L, VanLandingham M. Adherence to travel health guidelines: the experience of Nigerian immigrants in Houston, Texas. J Immigr Health 2001;3(1):31-45.

32 Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health 2005;10(4):355-72.

33 Abraham C, Clift S, Grabowski P. Cognitive predictors of adherence to malaria prophylaxis regimens on return from a malarious region: a prospective study. Soc Sci Med 1999;48(11):1641-54.

34 Keystone JS, Dismukes R, Sawyer L, Kozarsky PE. Inadequacies in health recommendations provided for international travelers by North American travel health advisors. J Travel Med 1994;1(2):72-8.

35 Held TK, Weinke T, Mansmann U, Trautmann M, Pohle HD. Malaria prophylaxis: identifying risk groups for non-compliance. Q J Med 1994;87(1):17-22.

36 Hatz C, Krause E, Grundmann H. Travel advice: a study among Swiss and German general practitioners. Trop Med Int Health 1997;2(1):6-12.

37 Plourde PJ, Tepper M, Schofield S. Statement on personal protective measures to prevent arthropod bites– update. Committee to Advise on Tropical Medicine and Travel (CATMAT). CCDR 2005;31(ACS13):1-20.

38 Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002;347(1):13-8.

39 Rowland M, Freeman T, Downey G, Hadi A, Saeed M. DEET mosquito repellent sold through social marketing provides personal protection against malaria in an area of all-night mosquito biting and partial coverage of insecticide-treated nets: a case-control study of effectiveness. Trop Med Int Health 2004;9(3):343-50.

40 Pest Management Regulatory Agency, Health Canada. Personal Insect Repellents Containing DEET(N,Ndimethyl- m-toluamide) and Related Compounds. 2002. Report No.: Re-evaluation Decision Document RRD2002-01.

41 Schreck C, Kline D. Personal protection afforded by control-release topical repellents and permethrin-treated clothing against natural populations of Aedes taeniorhychus. J Am Mosq Control Assoc 1989;5:77-80.

42 Domb AJ, Marlinsky A, Maniar M, Teomim L. Insect repellent formulations of N,N-diethyl-mtoluamide (DEET) in a liposphere system: efficacy and skin uptake. J Am Mosq Control Assoc 1995;11(1):29-34.

43 Montemarano AD, Gupta RK, Burge JR, Klein K. Insect repellents and the efficacy of sunscreens. Lancet 1997;349(9066):1670-1.

44 Pest Management Regulatory Agency, Health Canada. P-Menthane-3,8-diol. 2002. Report No.: Proposed Regulatory Decision Document PRDD2002-02.

45 Pest Management Regulatory Agency, Health Canada. Soybean oil. 1999. Report No.: Proposed Regulatory Decision Document PRDD99-02.

46 Yap HH, Jajangir K, Zairi J. Field efficacy of four distinct repellent products against vector mosquitoes in a tropical environment. J Am Mosq Control Assoc 2000;16(3):241-4. 47 Abramowicz M, ed. Picardin–a new insect repellent. Med Lett Drugs Ther 2005;


48 Choi HW, Breman JG, Teutsch SM, Liu S, Hightower AW, Sexton JD. The effectiveness of insecticideimpregnated bed nets in reducing cases of malaria infection: a meta-analysis of published results. Am J Trop Med Hyg 1995;52(5):377-82.

49 Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998;128(11):931-40.

50 Lengeler C, Cattani J, Savigny D, eds. Net Gain: A New Method for Preventing Malaria Deaths. World Health Organization and International Development Research Centre. 1996.

51 Msangi S, Lyatuu E, Masenga C, Kihumo E. The effects of washing and duration of use of longlasting insecticidal nets (PermaNets) on insecticidal effectiveness. Acta Trop 2008;107(1):43-7.

52 Schreck CE, Posey K, Smith D. Durability of permethrin as a potential clothing treatment to protect against blood-feeding arthropods. J Econ Entomol 1978;71(3):397-400.

53 Schoepke A, Steffen R, Gratz N. Effectiveness of personal protection measures against mosquito bites for malaria prophylaxis in travelers. J Travel Med 1998;5(4):188-92.

54 Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ 2003:169(3):209-12.

55 Wang T, Gu X. In vitro percutaneous permeation of the repellent DEET and the sunscreen oxybenzone across human skin. J Pharm Pharm Sci 2007;10(1):17-25.

56 Sanchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993;341(8851):1021-2.

57 Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126(12):963-72.

58 Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against Falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995;171(6):1569-75.

59 Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebocontrolled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999;60(4):521-5.

60 Shanks GD, Kremsner PG, Sukwa TY, Van Der Berg JD, Shapiro TA, Scott TR, Chulay JD. Atovaquone and proguanil hydrochloride for prophylaxis of malaria. J Travel Med 1999;6:S21-S27.

61 Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, Scott TR. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium Falciparum malaria. Clin Infect Dis 1998;27(3):494-9.

62 Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963- 2001. Ann Intern Med 2004;141(7):547-55.

63 Centers for Disease Control and Prevention. Malaria deaths following inappropriate malaria chemoprophylaxis– United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50(28):597-9.

64 Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998;351(9104):709-13.

65 Shwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria–implications for chemoprophylaxis in travelers. N Engl J Med 2003;349(16):1510-6.

66 Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2(4):209-18.

67 Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimasarn K. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 2001;32(1):41-9.

68 Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004;38(12):1716-23.

69 Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub- Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003;327(7423):1078-81.

70 Kozarsky P, Arguin P, Navin A. Malaria. In: CDC Health Information for International Travel, 2005-2006. Philadelphia: Elsevier Mosby, 2005.

71 Krudsood S, Patel SN, Tangpukdee N, Thanachartwet W, Leowattana W, Pornpininworakij K et al. Efficacy of atovaquone-proguanil for treatment of acute multidrugresistant Plasmodium Falciparum malaria in Thailand. Am J Trop Med Hyg 2007;76(4):655-8.

72 Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004;48(11):4075-83.

73 Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petruccelli BP. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005;293(2):212-6.

74 Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75(3):402-15.

75 World Health Organization. International Travel and Health. Geneva: World Health Organization, 2008.

76 Bradley DJ, Bannister B. Health Protection Agency ACMP for UK travelers, Guidelines for malaria prevention in travelers from the United Kingdom for 2003. Commun Dis Public Health 2003;6(3):180-199. Recommandations canadiennes pour la prévention et le traitement du Paludisme (Malaria) chez les voyageurs internationaux - 2009 77

77 Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet1993;341(8849):848-51.

78 Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341(8856):1299-303.

79 Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992;166(6):1462-4.

80 Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R et al. Efficacy of atovaquone/ proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002;35(10):1147-54.

81 Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ, Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997;175(4):871-5.

82 Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986;314(5):280-4.

83 Klein JL, Millman GC. Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics. BMJ 1998;316(7142):1425-6.

84 Bottieau E, Clerinx J, Van Gompel A, Van Esbroeck M, Wocjiechowski M, Van den Ende J. Etiology and outcome of imported fevers in children. 9th Conference of the International Society of Travel Medicine. May 1-5, 2005. Lisbon, Portugal.

85 Public Health Agency of Canada. Notifiable Diseases On-Line. Notifiable Disease, Malaria, 1999-2004.

86 Statistics Canada. Table 20: Trip characteristics of Canadian residents returning after a stay of one or more nights abroad. In: International Travel. 2008.

87 Maitland K, Marsh K. Pathophysiology of severe malaria in children. Acta Trop 2004;90(2):131-40.

88 Pickering LK, ed. Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, Illinois: American Academy of Pediatrics, 2006.

89 Parfit K, Martindale. The Complete Drug Reference, 35th ed. London: Pharmaceutical Press, 2008.

90 Smith ER, Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005;28(4):437-43.

91 Centers for Disease Control and Prevention. Information for health care providers: preventing malaria in infants and children. 2006. Available from: htm.

92 Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr 1996;16(4):281-6.

93 Stauffer WM, Kamat D, Magill AJ. Traveling with infants and children. Part IV: insect avoidance and malaria prevention. J Travel Med 2003;10(4):225-40.

94 Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007;76(2):208-23.

95 Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for Falciparum malaria. Lancet 1987;1(8543):1161-4.

96 Rietveld AE. Special groups: pregnant women, infants, and young children. In: Schlagenhauf-Lawlor P, ed. Travelers' Malaria, 1st ed. Hamilton: BC Decker Inc., 2001:303-23.

97 Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001;33(7):1015-21.

98 Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 2003;97(1):30-5.

99 Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, Walraven G. Effect of pregnancy on exposure to malaria mosquitoes. Lancet 2000;355(9219):1972.

100 McGready R, Hamilton KA, Simpson JA, Cho T, Luxemburger C, Edwards R et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg 2001;65(4):285-9.

101 Na-Bangchang K, Manyando C, Ruengweerayut R, Kioy Mulenga M, Miller GB, Konsil J. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated Falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 2005;61(8):573-82.

102 Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999;28(4):808-15.

103 Balocco RB, Bonati M. Mefloquine prophylaxis against malaria for female travelers of childbearing age. Lancet 1992;340:309-10.

104 Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, Heymann DL, Breman JG. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 1996;55(1):24-32.

105 Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998;58(1):17-21.

106 Nosten F, Terkuile F, Maelankiri L, Chong suphajaisiddhi T, Nopdonrattakoon L, Tangkitchot S et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994;169(3):595-603.

107 Hogh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Gunther M et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000;356(9245):1888-94.

108 Ward RM, Bates BA, Benitz WE, Burchfield DJ. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-89.

109 Frame JD, Lange WR, Frankenfield DL. Mortality trends of American missionaries in Africa, 1945-1985. Am J Trop Med Hyg 1992;46(6):686-90.

110 Schneider G. Malaria prevention for long-term workers overseas, choice or necessary evil? [dissertation]. University of London, London School of Hygiene and Tropical Medicine, 1998.

111 Adera T, Wolfe MS, McGuirerugh K, Calhoun N, Marum L. Risk factors for malaria among expatriates living in Kampala, Uganda: the need for adherence to chemoprophylactic regimens. Am J Trop Med Hyg 1995;52(3):207-12.

112 Lobel HO, Varma JK, Miani M, Green M, Todd GD, Grady K, Barber AM. Monitoring for mefloquineresistant Plasmodium Falciparum in Africa: implications for travelers' health. Am J Trop Med Hyg 1998;59(1):129-32.

113 Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol(Copenh) 1967;S:5.

114 Ducousso F, Ballion JC, Kovalski JL, Labrouze JM, Bazin S, Bourguignon G, Saliou G. Antimalarial macular intoxication: a case report. J Fr Ophtalmol 1995;18(8-9):553-8.

115 Balo KP, Mensah A, Mihluedo H. Chloroquine maculopathy and prophylaxy of malaria. J Fr Ophtalmol 1996;19(12):770-6.

116 Lange WR, Frankenfield DL, Moriarty-Sheehan M, Contoreggi CS, Frame JD. No evidence for chloroquineassociated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg 1994;51(4):389-92.

117 Bertagnolio S, Tacconelli E, Camilli G, Tumbarello M. Case report: retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 2001;65(5):637-8.

118 Lobel HO, Bernard KW, Williams SL, Hightower AW, Patchen LC, Campbell CC. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen. JAMA 1991;265(3):361-4.

119 World Health Organization. Report of the 11th WHOPES Working Group meeting; 2007 Dec 10-13. Geneva, Switzerland: World Health Organization, 2008.

120 Funk M, Schlagenhauf P, Tschopp A, Steffen R. MalaQuick versus ParaSight F as a diagnostic aid in travellers' malaria. Trans R Soc Trop Med Hyg 1999;93(3): 268-72.

121 Schlagenhauf P, Steffen R, Tschopp A, Van DP, Mittelholzer ML, Leuenberger H, Reinke C. Behavioural aspects of travellers in their use of malaria presumptive treatment. Bull World Health Organ 1995;73(2):215-21.

122 Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2(5):e100.

123 Newton PN, Proux S, Green M, Smithuis FM, Rozendaal J, Prakongpan S, Chotivanich K, Mayxay M et al. Fake artesunate in Southeast Asia. Lancet 2001;357(9272):1948-50.

124 Dondorp AM, Newton PN, Mayxay M, Van DW, Smithuis FM, Yeung S et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004;9(12):1241-6.

125 Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 2006 Nov 8;296(18): 2234-44.

126 World Health Organization. Guidelines for the Treatment of Malaria. Geneva, Switzerland: World Health Organization, 2006.

127 Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N et al. Effect of Plasmodium Falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005;365 (9455):233-40.

128 Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006;314(5805):1603-6.

129 Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999;4(1):5-12.

130 Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Sewankambo N, Lutalo T et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003;17(17):2539-41.

131 Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 2006;193:9-15.

132 Committee to Advise on Tropical Medicine and Travel (CATMAT). The immunocompromised traveler. CCDR 2007;33:1-24.

133 Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005;19(10):995-1005.

134 Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004;190:1998-2000.

135 Chotivanich K, Udomsangpetch R, McGready R, Proux S, Newton P, Pukrittayakamee S et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002;185:1538-41.

136 Bach O, Baier M, Pullwitt A, Fosiko N, Chagaluka G, Kalima M et al. Falciparum malaria after splenectomy: a prospective controlled study of 33 previously splenectomized Malawian adults. Trans R Soc Trop Med Hyg 2005;99(11):861-7.

137 Demar M, Legrand E, Hommel D, Esterre P, Carme B. Plasmodium Falciparum malaria in splenectomized patients: two case reports in French Guiana and a literature review. Am J Trop Med Hyg 2004;71(3):290-3.

138 Richter J, Burbach G, Hellgren U, Dengler A, Bi enzle U. Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet 1997;349(9045):101-2.

139 Touze JE, Heno P, Fourcade L, Deharo JC, Thomas G, Bohan S et al. The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 2002;67(1):54-60.

140 Westfall LK, Mintzer DL, Wiser TH. Potentiation of warfarin by tetracycline. Am J Hosp Pharm 1980;37(12):1620,1625.

141 Warfarin potentiated by proguanil. BMJ. 1991;303(6805):789.

142 Loefler I. Mefloquine and anticoagulant interaction. J Travel Med 2003;10(3):194-5.

143 Doxycycline [product monograph] 2007. Doxycycline: Cautions (Drug Interactions).

144 Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Travel Med 1999;6(2):122-33.

145 Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995;155(8):861-8.

146 Svenson JE, Gyorkos TW, MacLean JD. Diagnosis of malaria in the febrile traveler. Am J Trop Med Hyg 1995;53(5):518-21.

147 Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis 1998;27(1):142-9.

148 Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004;329(7476):1212.

149 Strickland GT. Hunter's Tropical Medicine and Emerging Infectious Diseases. 8th ed. Philadelphia: W.B. Saunders Company, 2000.

150 Marx A, Pewsner D, Egger M, Nuesch R, Bucher HC, Genton B, Hatz C, Juni P. Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med 2005;142(10):836-46.

151 Health Canada. Medical Devices Active Licence: Malaria. Products DH, ed. 2008.

152 Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat Rev Microbiol 2006;4(9):682-95.

153 Farcas GA, Zhong KJ, Lovegrove FE, Graham CM, Kain KC. Evaluation of the binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am J Trop Med Hyg 2003;69(6):589-92.

154 Jelinek T, Amsler L, Grobusch MP, Nothdurft HD. Self-use of rapid tests for malaria diagnosis by tourists. Lancet 1999;354:1609.

155 Whitty CJM, Armstrong M, Behrens RH. Self-testing for Falciparum malaria with antigen-capture cards by travelers with symptoms of malaria. Am J Trop Med Hyg 2000;63(5-6):295-7.

156 Trachsler M, Schlagenhauf P, Steffen R. Feasibility of a rapid dipstick antigen-capture assay for self-testing of travellers' malaria. Trop Med Int Health 1999;4(6):442-7.

157 Chilton D, Malik AN, Armstrong M, Kettelhut M, Parker-Williams J, Chiodini PL. Use of rapid diagnostic tests for diagnosis of malaria in the UK. J Clin.Pathol 2006;59:862-6.

158 Iqbal J, Siddique A, Jameel M, Hira PR. Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance of Plasmodium Falciparum monoinfection. J Clin Microbiol 2004;42(9): 4237-41.

159 Jelinek T, Grobusch MP, Schwenke S, Steidl S, von Sonnenburg F, Nothdurft HD et al. Sensitivity and specificity of dipstick tests for rapid diagnosis of malaria in nonimmune travelers. J Clin Microbiol 1999;37:721.

160 Lee N, Baker J, Andrews KT, Gatton ML, Bell D, Cheng Q, McCarthy J. Effect of sequence variation in Plasmodium Falciparum histidine-rich protein 2 on binding of specific monoclonal antibodies: implications for rapid diagnostic tests for malaria. J Clin Microbiol 2006;44(8):2773-8.

161 Hawkes M, Kain KC. Advances in malaria diagnosis. Expert Rev Anti Infect Ther 2007;5(3):485-95.

162 Farcas GA, Zhong KJ, Mazzulli T, Kain KC. Evaluation of the RealArt Malaria LC real-time PCR assay for malaria diagnosis. J Clin Microbiol 2004;42: 636-8.

163 Farcas GA, Soeller R, Zhong K, Zahirieh A, Kain KC. Real-time polymerase chain reaction assay for the rapid detection and characterization of chloroquineresistant Plasmodium Falciparum malaria in returned travelers. Clin Infect Dis 2006;42:622-7.

164 Legros F, Bouchaud O, Ancelle T, Arnaud A, Cojean S, Le Bras J et al. Risk factors for imported fatal Plasmodium Falciparum malaria, France, 1996-2003. Emerg Infect Dis 2007;13(6):883-8.

165 Bruneel F, Hocqueloux L, Alberti C, Wolff M, Chevret S, Bedos JP et al. The clinical spectrum of severe imported Falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003;167(5):684-9.

166 Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995;332(21):1399-404.

167 Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ et al. UK malaria treatment guidelines. J Infect 2007;54(2):111-21.

168 Yu B. Examination of blood smears for malaria parasites. Toronto: Laboratories Branch, Ontario Ministry of Health and Long-term Care, 2005.

169 Garcia LS, Johnston SP, Linscott AJ, Shimizu RY. Laboratory procedures for diagnosis of blood-borne parasitic diseases. Washington: American Society of Microbiology Press, 2008.

170 Craig MH, Bredenkamp BL, Williams CH, Rossouw EJ, Kelly VJ, Kleinschmidt I et al. Field and laboratory comparative evaluation of ten rapid malaria diagnostic tests. Trans R Soc Trop Med Hyg 2002;96(3):258-65.

171 Bigaillon C, Fontan E, Cavallo JD, Hernandez E, Spiegel A. Ineffectiveness of the Binax NOW malaria test for diagnosis of Plasmodium ovale malaria. J Clin Microbiol 2005;43(2):1011.

172 Mueller I, Betuela I, Ginny M, Reeder JC, Genton B. The sensitivity of the OptiMAL rapid diagnostic test to the presence of Plasmodium Falciparum gametocytes compromises its ability to monitor treatment outcomes in an area of Papua New Guinea in which malaria is endemic. J Clin Microbiol 2007;45(2):627-30.

173 Swarthout TD, Counihan H, Senga RK, van den Broek I. Paracheck-Pf accuracy and recently treated Plasmodium Falciparum infections: is there a risk of over-diagnosis? Malar J 2007;6:58.

174 Mishra SK, Das BS. Malaria and acute kidney injury. Semin Nephrol 2008;28(4):395-408.

175 World Health Organization. Management of Severe Malaria: A Practical Handbook. 2nd ed. Geneva, Switzerland: World Health Organization, 2000.

176 Lomar AV, Vidal JE, Lomar FP, Barbas CV, de Matos GJ, Boulos M. Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis 2005;9(5):425-30.

177 Muhlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M et al. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 2004;3:5.

178 Ozen M, Gungor S, Atambay M, Daldal N. Cerebral malaria owing to Plasmodium vivax: case report. Ann Trop Paediatr 2006;26(2):141-4.

179 Tanios MA, Kogelman L, McGovern B, Hassoun PM. Acute respiratory distress syndrome complicating Plasmodium vivax malaria. Crit Care Med 2001;29(3):665-7.

180 Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: severe malaria. Crit Care 2003;7(4):315-23.

181 Group, S.E.A.Q.A.M.T., Artesunate versus quinine for treatment of severe Falciparum malaria: a randomized trial. Lancet 2005;366:717-25.

182 Prasad K, Garner P. Steroids for treating cerebral malaria. Cochrane Database Syst Rev 1999;(3):CD000972.

183 Nieuwenhuis JA, Meertens JH, Zijlstra JG, Ligtenberg JJ, Tulleken JE, van der Werf TS. Automated erythrocytapheresis in severe Falciparum malaria: a critical appraisal. Acta Trop 2006;98(3):201-6.

184 Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium Falciparum malaria: a meta-analysis. Clin Infect Dis 2002;34:1192-8.

185 Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R et al. Atovaquone/proguanil therapy for Plasmodium Falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002;35(9):e92-5.

186 Chinevere TD, Murray CK, Grant E, Jr., Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6- phosphate dehydrogenase deficiency in U.S. army personnel. Mil Med 2006;171(9):905-7.

187 Smoak BL, DeFraites RF, Magill AJ, Kain KC, Wellde BT. Plasmodium vivax infections in U.S. army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 1997;56(2):231-4.

188 White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008;46(2):172-3.

189 Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in northwest frontier province, Pakistan. PLoS ONE. 2008 Aug 6;3(8):e2861.

190 Jones KL, Donegan S, Lalloo DG, 2007. Artesunate versus quinine for treating severe malaria. Cochrane Database Systematic Review: CD005967.

191 Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007;297(20):2251-63.

192 Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev 2008;21(3):466-72.

193 Schlagenhauf P. Standby emergency treatment by travelers. In: Schlagenhauf P, ed. Traveler's Malaria. 1st ed. Hamilton, ON: BC Decker Inc., 2001:261-9.

194 Swales CA, Chiodini PL, Bannister BA. New guidelines on malaria prevention: a summary. J Infect 2007;54(2):107-10.

195 World Health Organization. WHO Expert Committee on Malaria: Twentieth Report. Geneva, Switzerland: World Health Organization, 2000. Report No. 892.

196 Nothdurft HD, Jelinek T, Pechel SM, Hess F, Maiwald H, Marschang A et al. Stand-by treatment of suspected malaria in travellers. Trop Med Parasitol 1995;46(3):161-3.

197 Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45(1):86-91.

198 Luxemburger C, Nosten F, ter Kuiile F, Frejacques L, Chongsuphajaisiddhi T, White NJ. Mefloquine for multidrug-resistant malaria. Lancet 1991;338(8777):1268.

199 World Health Organization. International Travel and Health. Geneva, Switzerland: World Health Organization, 2005.

200 Davis TM, Karunajeewa HA, Ilett KF. Artemisininbased combination therapies for uncomplicated malaria. Med J Aust 2005;182:181-5.

201 Omari AA, Gamble C, Garner P. Artemetherlumefantrine (six-dose regimen) for treating uncomplicated Falciparum malaria. Cochrane Database Syst Rev 2005;(4):CD005564.

202 Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database Syst Rev 2005;(4):CD004531.

203 Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27(1):25-61.

204 Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated Falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 2004;98:261-7.

205 Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar J 2007;6:15.

206 Malarone (atovaquone/proguanil) [product monograph]. Mississauga, Ontario. GlaxoSmithKline Inc. 2005.

207 Peterson E. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev Anti Infect Ther 2004;2(1):119-32.

208 Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 2005;3(6):849-61.

209 Osei-Akoto A, Orton L, Owusu-Ofori SP. Atovaquoneproguanil for treating uncomplicated malaria. Cochrane Database Syst Rev 2005;(4):CD004529.

210 Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium Falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003;37(3):451-1.

211 Kuhn S, Gill MJ, Kain KC. Emergence of atovaquoneproguanil resistance during treatment of Plasmodium Falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg 2005;72(4):407-9.

212 Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM et al. Evidence of Plasmodium Falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003;326(7390):628-9.

213 Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States. JAMA 2007;297(20):2264-77.

214 Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 1991;77(3):416-20.

215 Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001;33(2):226-34.

216 Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 2001;33(3):381-5.

217 Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003;37(12):1659-67.

218 Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am 2005;19(1):185-210.

219 Shanks GD. Treatment of Falciparum malaria in the age of drug resistance. J Postgrad Med 2006;52(4):277-80.

220 Fontanet AL, Houze S, Keundjian A, Schiemann R, Ralaimazava P, Durand R et al. Efficacy of antimalarial chemoprophylaxis among French residents travelling to Africa. Trans R Soc Trop Med Hyg 2005;99(2):91-100.

221 Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Bélard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmüller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG., Fixed-Dose Pyronaridine-Artesunate Comination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. J Infect Dis. 2008 Sep 15;198(6):911-9.

222 Kofoed K, Petersen E. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. J Travel Med 2003;10(3):150-4.

223 Sutherland CJ, Haustein T, Gadalla N, Armstrong M, Doherty JF, Chiodini PL. Chloroquine-resistant Plasmodium Falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrob Chemother 2007;59(6):1197-9.

224 Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium Falciparum malaria. Clin Infect Dis 2001;33(12):1968-74.

225 Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 2000;355(9220):2041-5.

226 Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999;28:74-81.

227 Croft AM. Malaria: prevention in travellers. Clin Evid 2003;(10)911-30.

228 Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 2005;65(1):75-87.

229 World Health Organization. Susceptibility of Plasmodium Falciparum to Antimalarial Drugs: Report on Global Monitoring: 1996-2004. Geneva, Switzerland: World Health Organization, 2005.


Détails de la page

Date de modification :